According to the company, the approval of Zunveyl offers a novel approach with a dual mechanism of action designed to improve tolerability and efficacy in the treatment of Alzheimer’s disease.
FDA Approves Alpha Cognition’s Zunveyl for Oral Treatment of Mild to Moderate Alzheimer’s Disease
Leave a comment
